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Curve to Design a Predictive Genetic Test,
Exemplified with Type 2 Diabetes
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Current extensive genetic research into common complex diseases, especially with the completion of genome-wide association studies,
is bringing to light many novel genetic risk loci. These new discoveries, along with previously known genetic risk variants, offer an
important opportunity for researchers to improve health care. We describe a method of quick evaluation of these new ﬁndings for
potential clinical practice by designing a new predictive genetic test, estimating its classiﬁcation accuracy, and determining the sample
size required for the veriﬁcation of this accuracy. The proposed predictive test is asymptotically more powerful than tests built on any
other existing method and can be extended to scenarios where loci are linked or interact. We illustrate the approach for the case of type
2 diabetes. We incorporate recently discovered risk factors into the proposed test and ﬁnd a potentially better predictive genetic test.
The area under the receiver operating characteristic (ROC) curve (AUC) of the proposed test is estimated to be higher (AUC ¼ 0.671)
than for the existing test (AUC ¼ 0.580).Introduction
With the latest improvements and ever-decreasing costs of
high-throughput genotyping technologies, large-scale ge-
netic-association studies, and in particular genome-wide
association studies, are now being conducted. These stud-
ies provide a comprehensive scan of the whole genome
and have the potential to identify many more genetic
risk variants for common complex diseases. The new ﬁnd-
ings from these studies, together with previously known
genetic and environmental risk factors—whether or not
they increase our understanding of the etiology of com-
mon complex diseases—offer a potential opportunity for
researchers to improve medical care and public health.1
Some previous efforts aimed at combining genetic and
environmental ﬁndings to predict disease or, more pre-
cisely, to develop a predictive genetic test, are discussed
elsewhere.2–5 These are important ﬁrst steps toward the
development of successful predictive genetic tests for com-
mon complex diseases,6 and such tests have been recog-
nized as comprising the cornerstone of future genomic
medicine.7 The hope is that these tests will provide an early
discovery of an individual’s disease risk so that appropriate
prevention strategies can be used to reduce morbidity and
mortality. These tests are anticipated to have a large impact
on health care and change the form of health care away
from treatment toward prevention.8
However, these previous efforts have been limited by the
genetic and clinical information available at the time
the predictive genetic tests were developed. For instance,
the current predictive genetic test for type 2 diabetes is
based on three common variants.3 With the genome-
wide association studies that have now been conducted
for this disease and the novel susceptibility variants identi-ﬁed,9,10 one may want to know how much an existing test
could be improved by incorporating into it the newly dis-
covered genetic susceptibility variants.
The identiﬁcation of risk variants is a progressive pro-
cess, and so predictive genetic tests will also be subject to
change whenever novel genetic susceptibility variants are
discovered. This requires a ﬂexible and easily implemented
method for the redevelopment of predictive genetic tests
with time.6 In this paper, we propose a ﬂexible model to
help design a new predictive genetic test. Using informa-
tion garnered from published genetic-association studies,
clinical studies, and even a previously accepted predictive
genetic test, this approach provides an estimated classiﬁca-
tion accuracy of the proposed test and hence an idea of
how much improvement over an existing test a proposed
new test might achieve.
The clinical performance and applicability of a predictive
genetic test rests on four main components: (1) analytic
validity, (2) clinical validity, (3) clinical utility, and (4) asso-
ciated ethical, legal, and social implications.11 Our work
here focuses on addressing the clinical validity issue, de-
ﬁned as the ability of a genetic test to detect or predict
the associated disorder (phenotype). The assessment of
clinical validity is an important step and is the starting
point for test building. If the predictive genetic test dis-
criminates well among possible eventual outcomes, we
continue to evaluate its clinical utility. If, on the other
hand, it has poor accuracy, it is unlikely to have practical
value for patient care.12
In this paper, we ﬁrst derive a general formula to build
a predictive genetic test from previous independent associ-
ation results, extending it to situations where the genetic
variants are in linkage disequilibrium or interact with
each other. We then indicate how the requisite sample1Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio 44106, USA
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size can be calculated in order to design a study that will
have speciﬁed power at a given signiﬁcance level to be
sure that this new test attains a desired level of accuracy
or has a higher level of accuracy than the existing test.
Finally, we illustrate the model with recent association re-
sults that have become available for type 2 diabetes.
Material and Methods
Several approaches have been proposed for the evaluation of a pre-
dictive genetic test based on multiple disease-susceptibility loci.
Among them, the receiver operating characteristic (ROC) curve13
has been recognized as the most suitable measure.14,15 The ROC
curve plots a test’s true-positive rate (sensitivity) against its false-
positive rate (1-speciﬁcity) for continuously changing cutoffs
over the whole possible range of test results. It evaluates the tests
that result from these cutoffs with the entire spectrum of pairs of
true-positive rates (TPRs) and false-positive rates (FPRs) and so
gives a global description of a test’s classiﬁcation accuracy.16 The
ROC curve is also one of the most popular measures used for clin-
ical diagnostic tests and has been widely used in different areas of
medicine.17
Among all the techniques available for combining multiple pre-
dictors for ROC analysis, the logistic-regression-based approach
has been the most commonly used. However, as recent studies
have shown, logistic regression will not be optimal if the logistic
model does not hold.18 In the statistics literature, the optimality
of the likelihood ratio for ROC analysis has long been recog-
nized.19,20 The likelihood ratio—which in this context is deﬁned
as the ratio of two density functions of a predictor x, that among
cases to that among controls—is useful for the generation of the
appropriate (optimal) ROC curve. With Egan’s deﬁnition,20 the
optimal ROC curve results when this likelihood ratio is plotted
from its largest value to its smallest value. The optimal ROC curve
displays the best possible performance set based on the likelihood
ratio in terms of (1) the maximization of the TPR for any ﬁxed
value of the FPR, (2) the minimization of the overall misclassiﬁca-
tion probability, and (3) the minimization of the expected cost.
These three ideal properties could be obtained simply by the appli-
cation of the Neyman-Pearson lemma.20,21 Although the likeli-
hood ratio is ideal for ROC analysis, it was only recently empha-
sized for combining multiple predictors.21,22 Baker,22 who noted
the important role of the likelihood ratio for combining multiple
predictors, based his argument regarding its optimality by drawing
on cost-effectiveness theory23 rather than on the Neyman-Pearson
lemma. Despite this difference, the two arguments are essentially
the same, suggesting that for multiple predictors, a test based on
the likelihood ratio is optimal for any ﬁxed value of TPR or FPR.
This conclusion is elegant, but it has limitations if we are interested
in comparing testswithdifferent TPR andFPRpairs or in evaluating
the overall performance of the test. For the latter purpose, the ROC
curve or its summary indexes are the appropriate criteria to use.
Herewe choose the area under theROCcurve (AUC), themost pop-
ular summary index of the ROC curve, as a measure of a test’s per-
formance and prove that the optimal ROC curve has the highest
AUC (Appendix A). The AUC measures the probability that test
values from a randomly selected pair of diseased and nondiseased
individuals are correctly ordered and is thus a convenient global
measure for the quantiﬁcation of classiﬁcation (diagnostic) accu-
racy.12 This means that a test based on the optimal ROC curve642 The American Journal of Human Genetics 82, 641–651, Marchachieves the highest classiﬁcation accuracy among all approaches
(including a logistic-regression-based approach).
Building a Predictive Genetic Test on the Basis
of the Optimal ROC Curve
A General Model for Independent, Noninteracting Loci
Suppose we are interested in constructing a predictive genetic test
on the basis of variants at n genetic loci. From previous association
studies or other public sources, we obtain the relative risks esti-
mates ðRi ¼ ðri1,/,rimi ÞÞ and population genotype frequency esti-
mates ðFi ¼ ðfi1,/,fimi ÞÞ for the ith ði ¼ 1,/,nÞ associated locus,
which has mi possible genotypes. The distribution of these geno-
types at the ith locus in the disease (D) population can then be
derived from this information, with the formula
Pðgiji jDÞ ¼
riji fijiPmi
ji¼1 riji fiji
, ji ¼ 1,/,mi: (1)
The mi equations displayed in Equation 1 are appropriate for
a variety of genetic variants (in particular, single-nucleotide poly-
morphisms) with known mode of inheritance (Appendix B). The
equations can also be modiﬁed for the situation where the risk es-
timates are odds ratios (Appendix B). The information we can use
is not limited to that from association studies; it can also come
from other genetic studies (Appendix B).
If we assume linkage equilibrium among the n loci, we can
calculate the joint probability of the multilocus genotype
Gk ¼ ðg1ji ,g2j2 ,/,gnjn Þ from the single-locus-genotype frequencies,
PðGkÞ ¼
Yn
i¼1
Pðgiji Þ ¼
Yn
i¼1
fiji , ji ¼ 1,/,mi, k ¼ 1,/,K, (2)
where K denotes the total number of multilocus genotypes possi-
ble from the n disease-susceptibility loci and its maximal value is
m1$m2$.$mn. If we further adopt a multiplicative model, which
assumes that the joint effect of the n genetic variants is propor-
tional to the product of the individual variants’ main effects,
then the probabilities of themultilocus genotypesGk given disease
status can be expressed as
8><
>:
PðGk jDÞ ¼
Qn
i¼1
Pðgiji jDÞ
PðGk jDÞ ¼ PðGkÞ  PðGk jDÞr
1 r
, ji ¼ 1,/,mi, k ¼ 1,/,K, (3)
whereD denotes absence of disease and r denotes the disease prev-
alence. Given these probabilities, we can calculate the likelihood
ratios (LRs):
LRk ¼ PðGk jDÞ
PðGk jDÞ
, k ¼ 1,/,K: (4)
We rank the multilocus genotypes in descending order of their
LRs, from the highest rank to the lowest rank, and plot the test’s
TPR (sensitivity) against its FPR (1-speciﬁcity) for each possible
cutoff between adjoining pairs of multilocus genotypes that might
be used in the prediction of disease. This gives us the empirical
optimal ROC curve, which simply consists of a set of TPR and
FPR pairs:
8><
>:
TPRðkÞ ¼
Pk
k¼1
P

GðkÞjD

FPRðkÞ ¼
Pk
k¼1
P

GðkÞjD
 , k ¼ 1,/,K, (5)2008
whereGðkÞ is the k th genotype in the sequence of likelihood ratios.
Because the LRs are in descending order and the LRs correspond to
the slope of the ROC curve, this indicates that the optimal ROC
curve is always concave.
Once the optimal ROC curve has been built, we obtain the
explicit expression for the area under the optimal ROC curve by
applying the trapezoid rule:
AUC ¼ 1
2
XK
k¼1

TPRðkÞ þ TPRðk1Þ

,

FPRðkÞ  FPRðk1Þ

, (6)
where TPRð0Þ ¼ FPRð0Þ ¼ 0. This measures the estimated discrimi-
native ability of the test and leads to the highest value of the
AUC among all approaches to designing a predictive test. Other
statistics we might be interested in, such as predictive values,
can be directly obtained from the optimal ROC curve (Appendix
C). Proof of the optimality of the predictive values obtained
this way follows from the fact that the optimal ROC curve maxi-
mizes the TPR for any ﬁxed value of the FPR and the equations
in Appendix C.
Genetic Loci in Linkage Disequilibrium or Interacting with Each Other
The above model can be extended to incorporate loci that are in
linkage disequilibrium (LD) with each other. In this case, we are
interested in the multilocus genotypes formed by these linked
loci. Assume we have L linked loci, and for each locus we have
Kl ðl ¼ 1,/,LÞ alleles. Following a notation similar to that in Gor-
elick and Laubichler,24 we denote by Dnðkl,/Þ the coefﬁcients of
LD between n loci ðn ¼ 2,/,LÞ and byD1ðklÞ the population allele
frequency for the kl th ðkl ¼ 1,/,KlÞ allele at locus l. Assuming
that all possible LD coefﬁcient and population allele-frequency
estimates can be obtained from previous studies, we can express
the haplotype frequency ðphÞ for haplotype h ¼ ðk1, k2,., kLÞ
as the summation of all possible products of LD coefﬁcients
and allele frequencies whose orders (i.e., the number of loci) add
to L,
ph ¼
X
PS
s¼1 ns¼L
"YS
s¼1
Dns ð/Þ
#
, (7)
where Dns is the coefﬁcient of linkage disequilibrium between ns
loci24.
Normally, the coefﬁcients of LD with order higher than two are
rarely reported in genetic studies. Denote byD2ðkl, kl0 Þ the pairwise
LD between the alleles kl ðkl ¼ 1,/,KlÞ and kl0 ðkl0 ¼ 1,/,Kl0 Þ at loci
l and l0 ðl < l0; l ¼ 1,/,L 1Þ. Assuming that for each pair of loci
l and l0 all possible ðKl  1Þ3 ðKl0  1Þ pairwise LD coefﬁcient
estimates can be obtained from previous studies (in particular,
ðKl  1Þ3 ðKl0  1Þ ¼ 1 for SNPs), we can approximate the haplo-
type frequency by only using the pairwise LD (D2) and the popu-
lation allele frequencies ðD1Þ,
phz
X
PS
s¼1 ns ¼ L
ns%2
"YS
s¼1
Dns ð/Þ
#
: (8)
Given the haplotype frequency and the assumption of Hardy-
Weinberg equilibrium (HWE), we can derive the distribution for
the phased multilocus genotype gj ¼ ðhh0Þ,
fj ¼ pðgjÞ ¼

2phph0 hsh0
p2h h ¼ h0 , j ¼ 1,/,m:TheProvided that the haplotype-relative risk information rh is avail-
able, we can derive the relative risks for the phased multilocus
genotype gj ¼ ðhh0Þ, on the basis of an additive model, as
rgj ¼ rh þ rh0 , j ¼ 1,/,m:
Although the above equations assume an additive model, any
other model (e.g., recessive) can also be adopted according to
any prior knowledge of the disease. By treating these L linked
loci as comprising one set of genotypes and applying Equation
1, we can incorporate linked loci into the approach.
In a similar manner, we can extend the model to handle inter-
acting loci. In this scenario, we group all possible multilocus geno-
types from the interacting loci into a few clusters, each with a dif-
ferent associated disease risk. In the simplest situation, we have
just two clusters, a high-risk cluster and a low-risk cluster. At the
other extreme, eachmultilocus genotype itself represents a cluster.
Then, by obtaining the relative risks and the distribution of these
clusters, and again applying Equation 1, we can incorporate inter-
acting loci into the model.
We illustrate this by using a simple example. Assume there is an
interaction between two SNPs (A and B) and the underlying inter-
action follows a threshold model,25 deﬁned as implying there is
a single high risk for all individuals having at least one of the dis-
ease-susceptibility alleles at each of the two loci and a common
low risk for all other individuals. We denote by rr the relative
risk of the high-risk group ðg1Þ compared to the low-risk group
ðg0Þ and by f the population frequency of the high-risk group.
Then the distribution of the high- and low-risk groups in cases
can be written as (
Pðg1 jDÞ ¼ rr,f
rr,f þ 1 f
Pðg0 jDÞ ¼ 1 f
rr,f þ 1 f0
,
where, assuming Hardy-Weinberg equilibrium and that pA and
pB are the frequencies of the disease-susceptibility alleles for the
two loci, f ¼ pAð2 pAÞpBð2 pBÞ. Although we illustrate the
model by using genetic variants, the equations also apply for clin-
ical risk factors and to the situation where there is gene-environ-
ment interaction.
Sampling Variability of the Empirical AUC
and Comparison of Empirical ROC Curves
The above procedure provides an estimated classiﬁcation accuracy
of the new test in terms of the AUC. The estimated AUC could be
subject to large variability if the sample size is small. We introduce
here two methods for the calculation of the AUC variance, which
enables us to quantify its precision.
Asymptotically, the variance of the estimated AUCdepends only
on the ROC curve itself and the numbers of cases and controls:26
varAðAUCÞ ¼ varD
nD
þ varD
nD
, (9)
where nD and nD are the sample sizes of the disease and nondis-
ease samples and varD and varD are given by8><
>:
varD¼

1
2
PK
k¼1

TPRðkÞ þ TPRðk1Þ
2
,

FPRðkÞ  FPRðk1Þ
 AUC2
varD¼

1
2
PK
k¼1

FPRðkÞ þ FPRðk1Þ
2
,

TPRðkÞTPRðk1Þ
ð1AUCÞ2 :
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This provides a simple variance estimate when all the associated
genetic variants used for the test are based on one study. If the
genetic variants come from different studies, we cannot use the
above equations because nD and nD are not deﬁned. In this case,
we can adopt a bootstrap approach to estimate the variance. Sup-
pose the n genetic variants for the test are from U independent
studies. For the ith ði ¼ 1,/,nuÞ associated variant in the uth study
ðu ¼ 1,/,UÞ, we apply Equation 1 to compute its genotype fre-
quency in the case sample and repeat this step for all nu genetic
variants in the uth study. Further, by using Equations 2 and 3 to
combine these nu genetic variants, we can obtain the probabilities
of the multilocus genotypes given disease status. Given the total
number of diseased and nondiseased individuals in the uth study,
we can derive the observed numbers of all possible multilocus ge-
notypes given disease status. On the basis of these observed num-
bers, we draw a bootstrap sample and use the sample to calculate
the genotype frequencies, given disease status, for each of the nu
variants. We repeat this procedure for all the other U-1 studies
and then apply Equations 2–6 to construct the optimal ROC curve
and compute the AUC estimate. By drawing a large number of
bootstrap samples (e.g., 1000), we can obtain the bootstrap vari-
ance for the AUC estimate, denoted varBðAUCÞ. Although we illus-
trate the bootstrap approach for genetic variants, the same ap-
proach also applies for clinical risk factors and to the situation
where the genetic loci are in LD or interacting with each other.
With the variance estimates, we can easily determine the signif-
icance of the difference between two AUC estimates,A1 andA2, for
two different predictive tests. If the associated variants on which
the two tests are based come from different studies, the variance
of the AUC difference is equivalent to the sum of the variances
of the two AUC estimates,
varðA1  A2Þ ¼ varðA1Þ þ varðA2Þ ,
where varðA1Þ and varðA2Þ are the variances of A1 and A2. On that
basis, we construct an appropriate test statistic that under the null
hypothesis and in large samples follows a standard normal distri-
bution:
A1  A2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varðA1  A2Þ
p : (11)
If some or all of the associated variants on which the two tests
are based come from the same studies, then we need to take the
covariance of A1 and A2 into account. We can adopt the same
bootstrap approach here, but now forming two optimal ROC
curves from each bootstrap sample. The bootstrap variance of
the AUC difference can be expressed as
varBðA1  A2Þ ¼ varBðA1Þ þ varBðA2Þ  2covBðA1,A2Þ ,
where varBðA1Þ, varBðA2Þ, and covBðA1,A2Þ are the bootstrap vari-
ances of A1 and A2 and the bootstrap covariance between A1
and A2.
Sample-Size Calculation
If the classiﬁcation accuracy estimate (i.e., the AUC) of the new
test appears to be superior to existing tests, or if it reaches a desired
accuracy level, it might be worth further developing for clinical
use. However, the clinical validity of the test, i.e., its classiﬁcation
and/or prediction accuracy, should be comprehensively evaluated
before considering the test for clinical use.11 For that purpose,
a new replication study is necessary.27 Such a study serves the pur-
pose of verifying the test’s estimated classiﬁcation accuracy, which644 The American Journal of Human Genetics 82, 641–651, Marchhas been so far estimated on the basis of assumptions and informa-
tion from published genetic studies. To conduct the study, we set
up a hypothesis of interest and design the study with the requisite
sample size to test that hypothesis. If we assumeA0 is the AUC that
measures the classiﬁcation accuracy of a previous test, or is the
minimum desired level of classiﬁcation accuracy, we are interested
in knowing whether the performance of the new test is superior to
A0. Our null hypothesis for this purpose is H0 : A ¼ A0, with the
alternative HA : A > A0, where A is the AUC for the new test. An
appropriate sample size can then be determined that will ensure,
with speciﬁed power at an appropriate signiﬁcance level, that
the new test exceeds the minimal acceptable AUC value A0. For
this, we adopt the general approach based on asymptotic theory.28
Assume a and 1 b are the speciﬁed type I error and power we
require for our test; the required sample size for the test can
then be expressed as
nD ¼ ðp varD þ varDÞ

F1

1 aþF1ð1 bÞ
A A0
2
, (12)
where nD and nD are the sample sizes required for the disease
and nondisease samples, respectively, p ¼ nD=nD, and F is the
standard normal cumulative distribution function.
Application to Type 2 Diabetes
With the numerous genetic and clinical studies conducted so far,
our understanding of the causes of type 2 diabetes has greatly
improved. Thus, now might be the right time to begin applying
the more recent ﬁndings into clinical use, developing for type 2
diabetes a predictive test that combines all possible genetic vari-
ants and environmental factors. In particular, we use here novel
susceptibility loci that have been identiﬁed in recent genome-
wide association studies conducted for type 2 diabetes.9,10
Searching for a successful predictive genetic test for type 2 diabe-
tes has already been initiated. Recently, Weedon et al.3 used three
common variants, rs5219 (Glu23Lys) of KCNJ11, rs1801282
(Pro12Ala) of PPARG, and rs7903146 of TCF7L2, to predict the
risk of type 2 diabetes. We start with their study to test how con-
sistent the result from our approach is with their ﬁndings and
then investigate how much we might be able to improve their
test by utilizing the newer ﬁndings from genome-wide studies.
From the study by Weedon et al.,3 we obtained the allele fre-
quencies among cases and controls for the three variants.We com-
puted the genotype frequencies among cases and controls assum-
ing Hardy-Weinberg equilibrium for both the case and the control
populations. Applying Equation 3, we computed the multilocus
genotype probabilities given disease status, as detailed in Table 1.
From that, we could construct the optimal ROC curve (Figure 1).
The area under the optimal ROC curve is estimated to be 0.580
with Equation 6. The estimated standard error of the AUC is
0.0076 and 0.0075 with Equation 9 and the bootstrap approach,
respectively. If we chose 0.0076 as the estimate of the standard
error, the corresponding 95% conﬁdence interval (CI) for the
AUC is [0.565, 0.595]. The area under the optimal ROC curve
has exactly the same value as the one obtained from the logistic
regression performed in the original paper.3 This is not surprising,
because only three loci are involved in the test and there is no
evidence of interaction among these loci,3 so that the ROC curve
from linear logistic regression should well approximate the
optimal ROC curve. Also, from Figure 4 in the original paper,
the logistic-regression-based ROC curve is a concave curve that
corresponds closely to the optimal ROC curve.2008
Table 1. Calculation of an Optimal ROC Curve: Three SNPs
Allele Freq.a (Case;Control) Genotype Freq.b (Case;Population)
Multilocus Genotype
Freq.c (Case;Control)
Likelihood
Ratiod
Rank
Orderers5219 rs1801282 rs7903146 rs5219 rs1801282 rs7903146
rs5219x rs1801282x
rs7903146
0.384;0.354 0.099;0.123 0.384;0.3 0.147;0.126 0.010;0.015 0.147;0.093 0.0002;0.0002 1.236 7
0.473;0.423 0.0007;0.0006 1.086 11
0.379;0.484 0.0005;0.0006 0.954 15
0.178;0.214 0.147;0.093 0.0039;0.0024 1.590 3
0.473;0.423 0.0124;0.0089 1.394 6
0.379;0.484 0.0100;0.0082 1.223 9
0.812;0.771 0.147;0.093 0.0177;0.0086 2.052 1
0.473;0.423 0.0566;0.0316 1.794 2
0.379;0.484 0.0454;0.0289 1.570 4
0.473;0.458 0.010;0.015 0.147;0.093 0.0007;0.0008 0.855 16
0.473;0.423 0.0022;0.0029 0.753 19
0.379;0.484 0.0018;0.0027 0.663 23
0.178;0.214 0.147;0.093 0.0124;0.0114 1.094 10
0.473;0.423 0.0399;0.0415 0.962 13
0.379;0.484 0.0320;0.0378 0.846 17
0.812;0.771 0.147;0.093 0.0566;0.0404 1.402 5
0.473;0.423 0.1817;0.1476 1.231 8
0.379;0.484 0.1457;0.1349 1.080 12
0.379;0.415 0.010;0.015 0.147;0.093 0.0005;0.0009 0.590 24
0.473;0.423 0.0018;0.0034 0.521 26
0.379;0.484 0.0014;0.0031 0.459 27
0.178;0.214 0.147;0.093 0.0100;0.0133 0.753 20
0.473;0.423 0.0320;0.0483 0.663 22
0.379;0.484 0.0257;0.0440 0.584 25
0.812;0.771 0.147;0.093 0.0454;0.0473 0.960 14
0.473;0.423 0.1457;0.1725 0.845 18
0.379;0.484 0.1169;0.1572 0.743 21
Details of using the optimal ROC-curve approach for the three SNPs used by Weedon et al.3
a Allele-frequency estimates obtained from Weedon et al.3
b Genotype frequencies are computed assuming Hardy-Weinberg equilibrium separately for the case and the control populations.
c Multilocus genotype probabilities given disease status calculated with Equation 3.
d Likelihood ratios calculated with Equation 4.
e Rank order of the LRs.We can improve the existing genetic test for type 2 diabetes in at
least two ways. Clinical studies have shown that diet, physical
activity, cigarette smoking, and alcohol consumption affect the
risk of type 2 diabetes.29 These environmental factors could poten-
tially increase the accuracy of the test and, perhaps more impor-
tantly, there is the possibility that they interact with the genetic
variants to cause the disease.5,9 With regard to genetic variants,
a two-stage genome-wide association study has now been com-
pleted for type 2 diabetes.9 This study conﬁrmed the association
with rs7903146 in the TCF7L2 gene and, in addition, seven
SNPs were discovered representing four novel disease-susceptibil-
ity loci. We combined the information from these new loci, four
important environmental factors, and the three variants used in
the previous genetic test to create a new predictive genetic test.
To avoid overestimating the test’s discriminative ability, we chose
four SNPs from the seven new SNPs to represent the four novel
loci, removing the remaining three SNPs, which are in linkage dis-
equilibrium with the selected loci. The information for these four
novel loci, as well as for rs7903146, comes from the conﬁrmatory
stage (stage 2)9 of the study because estimates from that stage are
more reliable (i.e., from a well-designed, large-scale association
study). Partial details of the calculation are given in Table 2, andThewe ﬁnd that the estimated AUC for the new test is 0.657 (Figure 1).
In principle, we could also incorporate the three removed SNPs
into the tests if the haplotype risk estimates were available, and
then the estimated AUC would be even higher.
Since this paper was ﬁrst written, another genome-wide associ-
ation study has also been completed, and an additional ﬁve novel
disease risk loci have been discovered10 for type 2 diabetes. We
therefore obtained the estimates for these ﬁve disease risk loci
from the second stage of this genome-wide association study
and incorporated them also into the new predictive genetic test;
partial details of the calculation are given in Table 3. The estimated
AUC for the new test is now increased to 0.671 (Figure 1) with an
estimated standard error of 0.0071, and the corresponding 95% CI
is [0.657, 0.685]. In the near future, more and more disease risk
variants will no doubt be discovered,10 and the relation between
these variants (e.g., gene-gene interaction) will become clearer.
Thus, for type 2 diabetes, or any other disease, our approach could
be adopted to progressively incorporate newly discovered variants,
and eventually their interaction effects, gradually improving the
classiﬁcation accuracy of a predictive test.
Compared to the existing genetic test (AUC ¼ 0.580), the
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accuracy (AUC ¼ 0.671). To test the difference in these two AUC
values, we calculated
A1  A2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varBðA1  A2Þ
p ¼ 0:671 0:580
0:008
¼ 11:375;
where A1 and A2 are the AUC estimates for the proposed test and
existing test, respectively, and varBðA1  A2Þ is the bootstrap vari-
ance of A1  A2, taking the covariance into account. The corre-
sponding p value for the test is 2:831030. Although this result
is exceedingly signiﬁcant (owing to being based on an asymptotic
result and the large samples involved), the AUC estimates and this
test made certain assumptions (e.g., a multiplicative model).
Therefore, we should design a study to test whether this accuracy
can in fact be achieved. The requisite sample size can be calculated
to ensure that the new test has a higher level of accuracy than the
existing test. By using Equation 10, we can calculate the variances:
varD ¼ 0:072 and varD ¼ 0:074. Assuming a type I error rate (a)
of 0.05, power ð1 bÞ of 0.95, and equal numbers of cases and
controls ðp ¼ 1Þ, we compute the necessary sample size using the
general formula (Equation 12),
nD ¼ nD ¼ ð0:072þ 0:074Þ

1:645þ 1:645
0:671 0:580
2
z191 ,
i.e., 191 cases and 191 controls. Note that this particular sample
size also applies for testing our hypothesis with any choices of
type I error rate and power that satisfy F1ð1 aÞ þF1ð1 bÞ ¼
1:645þ 1:645 ¼ 3:29 (e.g., 1 b ¼ 0:8 and a ¼ 0:007).
Discussion
The importance and beneﬁt of predictive genetic tests have
been recognized by both researchers and the public.7,8,30–33
In a recent article, genetic tests have been described as the
cornerstone of genomic medicine.7 Although the beneﬁt
of predictive genetic testing is obvious and this opportunity
is important for the ﬁeld of medical genetics, work on this
topic is still limited. This is partly due to our limited knowl-
edge of genetic causes of common diseases.With the recent
intensive research on common diseases, especially with the
completion of genome-wide association studies, many
novel, apparently causal genes have already been discov-
ered, and variants of these genes, whether themselves
causal or not, could be usefully implemented into genetic
tests. For that purpose, we have described here a general
model to both design and evaluate a predictive genetic
test. By taking the information from previous, related asso-
ciation studies, our approach has the ability to estimate the
proposed test’s approximate discriminative ability. Byusing
this result, if it is encouraging, we can formulate a hypothe-
sis of interest to rigorously evaluate the proposed test, and
for this purpose, we have provided the formula for sam-
ple-size calculation. Our approach is easy to use. In a simple
scenario (e.g., for the rebuilt existing predictive genetic test
for type 2 diabetes), it can be implemented with Excel. We
have also provided sample R source code (OPMDesign.R)
on the website noted in the Web Resources.
Themodel we have introduced for the design of a predic-
tive genetic test is an illustration of the use of the original
optimality theory based on the likelihood ratio.19,20 This
theory indicates that a decision rule based on the likeli-
hood ratio is best. We have further shown that a test built
on the likelihood ratio can achieve the highest discrimina-
tive ability among all approaches. We incorporated these
ideal properties in designing a predictive genetic test for
type 2 diabetes. Our approach is similar to the approaches
introduced by Baker22 and McIntosh et al.21 The differ-
ences among the three approaches relate to the calculation
of the LR, or its one-to-one function, the risk score. Baker22
approached the LR by directly using the joint distributions
of predictors among cases and controls in the data,
whereas McIntosh et al.21 estimated the risk by logistic re-
gression. From a large-sample simulation21 and a real data
application,22 Baker’s approach showed a better perfor-
mance than did the logistic-regression approach,21 but
with an over-ﬁtting issue when the sample size is limited.
Amodel is liable to over-ﬁtting whenever toomany param-
eters are estimated for the sample size that is available.34
Baker approached the LR directly from the joint distribu-
tions of the predictors, with the result that the model com-
plexity increases exponentially with the number of predic-
tors, leading to an overly optimistic estimate of the ROC
performance. For example, if the test is based on n risk
SNPs, this approach requires 3n  1 genotype combination
frequencies to be estimated from each of the case and
Figure 1. ROC Curves for Type 2 Diabetes
The three lines in the plot from bottom to top correspond to the
ROC curves of three type 2 diabetes predictive tests: the rebuilt
existing predictive genetic test based on three SNPs, the new pre-
dictive test combing the previously associated SNPs, four environ-
mental factors, and four novel risk SNPs from the confirmatory
stage of the genome-wide association study,9 and the improved
new predictive test with five additional novel risk SNPs discovered
in the second genome-wide association study of type 2 diabetes.10
The estimated AUC values of these three tests are 0.580, 0.657, and
0.671, respectively.
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control samples. Our approach approximates the likeli-
hood ratios by utilizing the essential information of each
genetic variant from previous genetic studies and assumes
a multiplicative model. This not only allows us full use of
the information for single genetic variants, which is com-
monly obtained in genetic studies, but also helps mitigate
against over-ﬁtting. For the same example, our approach
needs only 2n genotype frequencies to be estimated from
each of the case and control samples to compute the fre-
quencies of all genotype combinations, and therefore the
model complexity is greatly reduced. Our approach can
use genetic variants with known mode of inheritance
and is easily extended to scenarios where the genetic vari-
ants are in linkage disequilibrium or interact with each
other. Incorporating this additional information can
make the approach more robust to the over-ﬁtting prob-
lem and increase the power of the approach. However,
the performance of the approach relies on the assumptions
Table 3. Calculation of an Optimal ROC Curve: Adding Five SNPs—One Shown—to the Calculations in Table 2
Environmental and Genetic
Risk Factors Combination
Frequencies from Previous
Testa (Case;Control)
Genotype Freq.b
(Case;Control)
Genotype Freq.
(Case;Population)
Environmental and
Genetic Risk Factors
Combination Frequencies
(Case;Control)
Likelihood
Ratio
Rank
PercentagecDietary Score x . x rs5219x. rs4402960 . rs4402960 . Dietary Score x . x rs4402960 x.
8.238e-09;1.450e-09 0.103;0.115 . 0.103;0.114 . 1.118e-11;1.160e-12 9.640 0.02%
. . . . . . . .
1.275e-08;2.767e-09 0.103;0.115 . 0.103;0.114 . 1.731e-11;2.300e-12 7.523 0.05%
. . . . . . . .
7.189e-09;1.806e-09 0.103;0.115 . 0.103;0.114 . 9.756e-12;1.534e-12 6.359 0.10%
. . . . . . . .
9.568e-09;2.869e-09 0.103;0.115 . 0.103;0.114 . 1.298e-11;2.492e-12 5.210 0.21%
. . . . . . . .
4.037e-09;1.767e-09 0.103;0.115 . 0.103;0.114 . 5.478e-12;1.589e-12 3.447 0.89%
. . . . . . . .
Details of using the optimal ROC-curve approach to further improve the new predictive genetic test in Table 2 by incorporating five additional novel risk
SNPs discovered in the second genome-wide association study of type 2 diabetes10 (five combinations only, out of a total of 23108 combinations).
a Multilocus genotype probabilities given disease status obtained from the new predictive genetic test in Table 2.
b Genotype frequency estimates obtained from the confirmatory stage (stage 2) of the second genome-wide association study.10
c 100(rank of LR)/(total number of combinations).
Table 2. Calculation of an Optimal ROC Curve: Adding Four SNPs—One Shown—and Four Environmental Factors—One Shown—
to the Calculations in Table 1
Information
for
Environmental
Risk Factorsa
(Percentage;
Relative Risk)
Allele
Freq.b
(Case;
Control)
Genotype
Freq.c
(Case;
Control)
Frequencies of
Environmentald
and Genetic
Risk Factors
(Case;
Population)
Environmental
and Genetic
Risk Factors
Combination
Frequencies
(Case;Control)
Likelihood
Ratio
Rank
PercentageeDietary Score . rs5219 . rs7903146 . Dietary Score . rs5219 . rs7903146 .
Dietary Score
x. x rs5219x.
0.150;1.000 . 0.384;0.354 . 0.163; 0.084 . 0.197;0.150 . 0.147;0.126 . 0.163;0.089 . 8.238e-09;1.450e-09 5.680 0.20%
. : . . . : . . . . . . . .
0.270;0.860 . 0.384;0.354 . 0.163; 0.084 . 0.305;0.270 . 0.147;0.126 . 0.163;0.089 . 1.275e-08;2.767e-09 4.608 0.50%
. : . . . : . . . . . . . .
0.170;0.770 . 0.384;0.354 . 0.163; 0.084 . 0.172;0.170 . 0.147;0.126 . 0.163;0.089 . 7.189e-09;1.806e-09 3.982 0.90%
. : . . . : . . . . . . . .
0.260;0.670 . 0.384;0.354 . 0.163; 0.084 . 0.229;0.260 . 0.147;0.126 . 0.163;0.089 . 9.568e-09;2.869e-09 3.335 1.75%
. : . . . : . . . . . . . .
0.150;0.490 . 0.384;0.354 . 0.163; 0.084 . 0.097;0.150 . 0.147;0.126 . 0.163;0.089 . 4.037e-09;1.767e-09 2.285 5..86%
. : . . . : . . . . . . . .
Details of using the optimal ROC-curve approach to combine the SNPs in Table 1, four environmental factors, and four novel risk SNPs from the first genome-
wide association study9 by assuming r ¼ 0:07 (five combinations only, out of a total of 93105 combinations).
a Distribution and relative risk of the environmental risk factors obtained from Hu et al.29
b Allele frequency estimates obtained from Weedon et al.3
c Genotype frequency estimates for cases and controls obtained from the confirmatory stage (stage 2) of the first genome-wide association study.9
d Distribution of the environmental factors in cases calculated by applying Equation 1.
e 100(rank of LR)/(total number of combinations).
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being satisﬁed and the accuracy of the information from
previous genetic studies. Assumption violation and inaccu-
rate information can bias the parameters of interest (e.g.,
the AUC). For instance, if we violate the assumption of
a multiplicative model and linkage equilibrium by incor-
porating all seven SNPs discovered from the ﬁrst genome-
wide association study into the test, the estimated AUC
will increase from 0.671 to 0.678. Although this does not
seem to affect the result too much, violation of the
assumptions when there is a large number of loci or loci
having strong effects (i.e., high relative risks) will cause
serious bias. In illustration of this, assume two loci near
each risk locus are also used for forming the test. If we as-
sume for simplicity that the two loci are in complete link-
age disequilibrium with the risk loci, then the estimated
AUC is increased to 0.750. To avoid introducing such
a bias, we can either apply the extended approach to incor-
porate these loci given the required information (i.e., the
LD estimates), if available, or we can simply remove these
extra loci—this leads to a conservative estimate, and the
design will still be valid.
We illustrated the proposed approach for the case of type
2 diabetes. The approach was ﬁrst examined with as an
example an existing predictive genetic test,3 and the result
fromtheoptimalROCcurvemethodwas found tobehighly
consistent with the one originally reported. This results
from the equivalence between the logistic-regression-based
ROC curve and the optimal ROC curve in such a simple sce-
nario (i.e., few loci, no interactions). To further improve the
predictive test, we incorporated further risk factors. With
both important environmental factors and novel loci dis-
covered from two recent genome-wide association studies
taken into account, the new predictive genetic test
(AUC¼0.671)couldhavea signiﬁcantlyhigherclassiﬁcation
accuracy (P ¼ 2:831030) than the existing test (AUC ¼
0.580). Because the variants involved in the new test are ei-
ther well studied or conﬁrmed, and the corresponding esti-
mates used came from well-designed, large-scale studies,
the estimated AUC value for this new test could be consid-
ered to be a reasonable approximation of the actual classiﬁ-
cation accuracy of the test. Because gene-gene and gene-
environmental interactions were not studied in the
previous association studies, we are unable to incorporate
these effects into the new proposed test. If there are strong
interaction effects among the predictors, our estimated
AUC value would tend to be conservative. The design to
study the test will still be valid because any strong interac-
tion effect would lead to a higher value of the AUC and
thus be in favor of the alternative hypothesis.
Unlike the current predictive genetic test, we also incor-
porated environmental risk factors into the new test—not
only because by themselves they can increase information
on risk to the disease, but also because they could interact
with the genetic variants to cause the disease. Without
considering them, we cannot study any gene-environmen-
tal effect in any proposed new test. The other advantage of
studying them is that in some scenarios we can use them as648 The American Journal of Human Genetics 82, 641–651, Marcha method to help disease prevention. For example, we
could use the equation in Appendix C to calculate the pos-
itive predictive values (PPV) for individuals who carry the
multilocus genotype with most risk. The chance of type
2 diabetes would then be predicted to decrease from
83.9% to 29.2% if they adopted a healthy life style (exer-
cise/week > 7 hr and dietary score ¼ 5) rather than having
a nonhealthy life style (exercise/week < 0.5 hr and dietary
score ¼ 1). Because the predictive genetic test can be con-
ducted at an early age, such as at birth, it would be rela-
tively easy to advise high-risk people to adopt a healthier
life style when they are young rather than make them
change behavior after the disease has been diagnosed.
Some researchers have suggested that it would be less
costly and more efﬁcient to conduct genetic tests for
only high-risk individuals (e.g., individuals with a family
history of disease), instead of for the general popula-
tion.35,36 We therefore also attempted to investigate
a predictive test for high-risk diabetes subjects on the basis
of results of the initial stage of the ﬁrst genome-wide asso-
ciation study.9We found that the resulting test could reach
a high level of classiﬁcation accuracy (AUC ¼ 0.855). How-
ever, this result would be liberal because the controls came
from the general population rather than from a subpopula-
tion of high-risk individuals. To conduct a genetic test on
a particular subgroup of the population requires that we in-
vestigate its performance on that subgroup. If a test ap-
pears to be superior to the one already in use for the general
population, it might be considered as a candidate for
a high-risk population, but it must ﬁrst be carefully tested
on such a population.
Our proposed approach should be a useful tool for de-
signing a predictive genetic test. It would help the investi-
gator explore possible hypotheses and make decisions re-
garding developing a new genetic test. It should function
as an exploratory phase of medical test development at lit-
tle cost. The performance of the approach depends on our
knowledge of disease-associated variants and the accuracy
of the estimates found in the published association studies.
The estimated test’s classiﬁcation accuracy will reﬂect the
actual test’s performance if the variants involved in the
test have been well studied and their estimates come
from well-planned studies. Otherwise, the estimate could
be subject to bias. Any result would only be valid for the
same population as that used for the association study
that produced the estimates, and not necessarily apply to
different populations, for which the risk estimates and
population frequency estimates could be different.
Appendix A
Proof that the Optimal ROC Curve Has
the Highest AUC
When we are dealing with multiple genetic variants, each
method combines multiple predictors differently and as-
signs its own unique score for each multilocus genotype.2008
Because the ROC curve relies only on the ranks of these
scores, not the absolute scores, the ROC curve from each
approach can be represented by the unique ranks of the
multilocus genotypes. Assuming o1 represents the ranks
of multilocus genotypes from the optimal ROC approach
and o2 represents those from any other approach, we prove
that the AUC from the optimal ROC approach ðAUCO1Þ is
always as great as, or greater than, that from any other
approach ðAUCO2Þ.
It is easy to show that the rank o2 can always be obtained
from o1 by a series of order switches between pairs of
multilocus genotypes. We prove that each order switch
from the original ranks of the optimal ROC curve can
only decrease, or leave unchanged, the AUC value. Assume
Pn ¼ ðpnð1Þ, pnð2Þ,/, pnðKÞÞ and Qn ¼ ðqnð1Þ, qnð2Þ,/, qnðKÞÞ are the
distributions of the multilocus genotypes in cases and
controls, respectively, from the nth order switch. At the
(nþ1)th step, we switch the order of the ith and
jth multilocus genotypes, and the corresponding distribu-
tions are then denoted Pnþ1 ¼ ðpnð1Þ,/, pnðjÞ,/, pnðiÞ,/, pnðKÞÞ
and Qnþ1 ¼ ðqnð1Þ,/, qnðjÞ,/, qnðiÞ,/, qnðKÞÞ. Simply by using
the trapezoid rule, we can calculate the difference in the
AUCs:
AUCn  AUCnþ1
¼ 1
2
ð2pn þ pnðiÞÞqnðiÞ þ
1
2
ð2pn þ 2pnðiÞ þ pnðiþ1ÞÞqnðiþ1Þ
þ/þ 1
2
 
2pn þ 2
Xj2
k¼i
pnðkÞ þ pnðj1Þ
!
qnðj1Þ
þ1
2
 
2pn þ 2
Xj1
k¼i
pnðkÞ þ pnðjÞ
!
qnðjÞ
1
2
ð2pn þ pnðjÞÞqnðjÞ 
1
2
ð2pn þ 2pnðjÞ þ pnðiþ1ÞÞqnðiþ1Þ
/ 1
2
 
2pn þ 2pnðjÞ þ 2
Xj2
k¼iþ1
pnðkÞ þ pnðj1Þ
!
qnðj1Þ
1
2
 
2pn þ 2pnðjÞ þ 2
Xj1
k¼iþ1
pnðkÞ þ pnðiÞ
!
qnðiÞ
¼ 1
2
ðpnðiÞqnðiÞ  pnðjÞqnðjÞÞ þ ðpnðiÞ  pnðjÞÞqnðiþ1Þ þ/
þðpnðiÞ  pnðjÞÞqnðj1Þ þ
1
2
ðpnðjÞqnðjÞ  pnðiÞqnðiÞÞ
þ
	Pj1
k¼i
pnðkÞ


qnðjÞ 
	
pnðjÞ þ
Pj1
k¼iþ1
pnðkÞ


qnðiÞ
¼ ðpnðiÞqnðjÞ  pnðjÞqnðiÞÞ þ ðpnðiÞqnðiþ1Þ  pnðiþ1ÞqnðiÞÞ
þ ðpnðiþ1ÞqnðjÞ  pnðjÞqnðiþ1ÞÞ þ/þ ðpnðiÞqnðj1Þ  pnðj1ÞqnðiÞÞ
þ ðpnðj1ÞqnðjÞ  pnðjÞqnðj1ÞÞ ,
where
pn ¼
Xi1
k¼1
pnðkÞ:
Because
pnðiÞ
qnðiÞ
R
pnðiþ1Þ
qnðiþ1Þ
R/R
pnðjÞ
qnðjÞ
,
AUCnRAUCnþ1
 
AUCn¼AUCnþ1 if and only if p
n
ðiÞ
qnðiÞ
¼ p
n
ðiþ1Þ
qnðiþ1Þ
¼/ ¼ p
n
ðjÞ
qnðjÞ
!
:
To satisfy the condition LRnðiÞRLR
n
ðiþ1ÞR/RLR
n
ðjÞðLRnðkÞ ¼
pnðkÞ=q
n
ðkÞ, k ¼ i,/, jÞ, the order of the ith to jth multilocus
genotypes must keep their original order as in o1. This
requirement also applies to other pair switches and may
limit the possible order changing but is always feasible.
Therefore, we obtain
AUCO1R/RAUCnRAUCnþ1R/RAUCO2 ,
and thus prove that the AUC of the optimal ROC curve is at
worst equal to that of any other approach. Because O2 is
arbitrary, the AUC of the optimal ROC curve is the highest
among all ROC curves.
Appendix B
Risk Estimates Measured as Odds Ratios
If the estimates of risk parameters for the genetic variants
are odds-ratio estimates, Equation 1 is no longer valid
unless we make the rare disease assumption. Under the
common disease scenario, we could still obtain Pðgiji jDÞ,
ji ¼ 1,/,mi, assuming there are mi possible (multilocus)
genotypes for the ith genetic variant. For each genotype,
we denote its odds ratio estimate ORiji ¼ PðDjgijiÞ=
PðDjgijiÞ=½PðDjgi1Þ=PðDjgi1Þ and the corresponding fre-
quency fiji, ji ¼ 1,/,mi. The probability of disease given ge-
notype, PðDjgijiÞ, ji ¼ 1,/,mi, can then be obtained from
the following mi equations,
8><
>>:
PðD j gijiÞ ¼
ORijiPðD j gi1Þ
1þ ORijiPðD j gi1Þ  PðD j gi1ÞPmi
ji¼1
PðD j gijiÞfiji ¼ r
, ji ¼ 1,/,mi :
ð13Þ
By applying Bayes’ rule, we have Pðgiji jDÞ,
Pðgiji jDÞ ¼
PðD j gijiÞ,fiji
r
, ji ¼ 1,/,mi : (14)
Genetic Variants Are SNPs
We assume the ith genetic variant is a SNP that has two
alleles, A and a. From a previous study, we obtain the geno-
type frequencies F ¼ ðf2,f1,f0Þ for genotypesG ¼ ðAA,Aa,aaÞ
and the relative risk rr2 ðrr1Þ, the risk for AA (Aa) divided by
that for aa. If the genotype frequencies are not available
from the previous study, we can estimate them from the
allele frequencies on the assumption of HWE. On the basis
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of Equation 1, we have the genotype distribution in the
disease population,8><
>:
PðAA jDÞ ¼ rr2f2
rr2f2 þ rr1f1 þ f0
PðAa jDÞ ¼ rr1f1
rr2f2 þ rr1f1 þ f0
Pðaa jDÞ ¼ f0
rr2f2 þ rr1f1 þ f0
: (15)
Further modifying the above equations, we can have a sim-
ilar expression for a different mode of inheritance. For in-
stance, if the variant A is dominant, we have the
following conditional probabilities:(
PðAA,Aa jDÞ ¼ rrðf2 þ f1Þ
rrðf2 þ f1Þ þ f0
Pðaa jDÞ ¼ f0
rrðf2 þ f1Þ þ f0
, (16)
where rr denote the relative risk of the genotypes with the
A allele versus the genotype without the A allele.
Using Information from Previous Genetic-Test Studies
If the genetic variants we are interested in have been
studied in an existing genetic test, we could also utilize
such information. From the ROC curve of the previous
genetic test, we can obtain the entire set of TPR and FPR
pairs. Assuming there are K TPR and FPR pairs, the dis-
tribution of genotype combinations among cases can be
derived as
PðGk jDÞ ¼ TPRðkþ1Þ  TPRðkÞ, k ¼ 1,/,K  1 ,
where the TPRðkÞ are the ordered TPRs from the left side to
the right of the ROC curve.
If we are only interested in some of the genetic variants,
we sum the above conditional probabilities over all genetic
variants of no interest and thus obtain the distribution for
the genetic variants of interest.
Appendix C
Calculating Predictive Values
For given disease prevalence r, the predictive values can be
simply calculated by Bayes’ rule:8<
:
PPVðkÞ ¼ TPRðkÞ,r
TPRðkÞ,rþ FPRðkÞ,ð1 rÞ
NPVðkÞ ¼

1 FPRðkÞ

,ð1 rÞ
1 FPRðkÞ

,ð1 rÞ þ 1 TPRðkÞ,r
, k ¼ 1,/,K:
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